menu
    • menu
    [{"orgOrder":0,"company":"Zentiva","sponsor":"Cinclus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zentiva","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"8","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Zentiva","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"}]

    Find Clinical Drug Pipeline Developments & Deals by Zentiva

    Menu

    Zentiva

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zentiva

                            Czech Republic arrow
                            AGGSpend
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Lupin Ltd

                            Deal Size : $60.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zentiva and Lupin Sign License and Supply Agreement for TNF Alpha Inhibitor Biosimilar

                            Details : The agreement aims for commercialization of Lupin's biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $10.0 million

                            July 09, 2025

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Lupin Ltd

                            Deal Size : $60.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zentiva

                            Czech Republic arrow
                            AGGSpend
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Cinclus Pharma

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe

                            Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $14.7 million

                            May 22, 2025

                            Lead Product(s) : Linaprazan Glurate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Cinclus Pharma

                            Deal Size : $249.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth